NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Wednesday, November, 6th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.49. The firm had revenue of $168 million for the quarter, compared to analyst estimates of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The business's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

11 Wall Street analysts have issued 1-year price targets for Ionis Pharmaceuticals' stock. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $76.60 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

Press coverage about IONS stock has trended extremely positive on Saturday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of 4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 9,110,000 shares, a decline of 9.2% from the October 31st total of 10,030,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 8.9 days. Approximately 7.1% of the company's stock are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.62%), Sicart Associates LLC (0.29%), Tocqueville Asset Management L.P. (0.29%), Stifel Financial Corp (0.29%) and Nikko Asset Management Americas Inc. (0.26%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Janney Montgomery Scott LLC, Tocqueville Asset Management L.P., State of New Jersey Common Pension Fund D, Man Group plc, Decatur Capital Management Inc., Nisa Investment Advisors LLC and Stifel Financial Corp. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, California Public Employees Retirement System, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Castleark Management LLC, Parametric Portfolio Associates LLC, Prospera Financial Services Inc and Pictet Asset Management Ltd.. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $64.61.

Ionis Pharmaceuticals has a market capitalization of $9.09 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.